obesity treatment with bariatric surgery vs glp-1 receptor agonists GLP1 (2025): Bariatric Surgery vs Receptor Agonists, ., ⛔️Disclaimer: This post is for educational and informational purposes only GLP-1 vs Bariatric Surgery Study:

Long-acting agents seem to have a lower incidence of gastrointestinal adverse effects (166), likely due to tachyphylaxis in gastric emptying with sustained GLP-1R stimulation

Nat Med (2022) 28:5918

This increase reflects a pattern of growing use of newer GLP-1s, such as Ozempic and Mounjaro, while use of older products, such as Byetta (approved in 2005), Victoza (approved in 2010), and Trulicity (approved in 2014), has declined

Lower doses might provide immunomodulatory benefits while minimizing these troublesome symptoms, potentially improving treatment adherence

GIP receptor activation complements the effects of GLP-1, further enhancing satiety and helping the body process and store nutrients more efficiently